

# Michelle L O donoghue

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6541034/michelle-l-odonoghue-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

3,951

citations

30

h-index

62

g-index

72

ext. papers

5,166

ext. citations

10.8

avg, IF

4.91

L-index

#	Paper	IF	Citations
62	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. <i>American Heart Journal</i> , <b>2022</b> , 243, 147-157	4.9	1
61	Antiplatelet therapy after percutaneous coronary intervention.. <i>EuroIntervention</i> , <b>2022</b> , 17, e1371-e1396	5.1	5
60	Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUTcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study.. <i>Thrombosis Research</i> , <b>2022</b> , 214, 122-131	8.2	0
59	Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And Lipoprotein(a) reduction-DOSE Finding Study) Trial.. <i>American Heart Journal</i> , <b>2022</b> , 251, 61-61	4.9	1
58	Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017401	6	6
57	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 675-681	5.1	3
56	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , <b>2021</b> , 143, 470-478	16.7	13
55	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , <b>2021</b> , 99, 926-939	9.9	6
54	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , <b>2021</b> , 64, 1226-1234	10.3	4
53	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , <b>2021</b> , 143, 685-695	16.7	3
52	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , <b>2021</b> , 143, 673-684	16.7	2
51	Increasing Participation of Women in Cardiovascular Trials: JACC Council Perspectives. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 737-751	15.1	10
50	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
49	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 709-713	16.2	25
48	The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Circulation</i> , <b>2020</b> , 142, 538-545	16.7	52
47	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , <b>2020</b> , 141, 1600-1607	16.7	32
46	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> ,	3.9	5

45	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , <b>2020</b> , 11, 163	17.4	140
44	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. <i>Circulation</i> , <b>2019</b> , 140, 1308-1317	16.7	85
43	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , <b>2019</b> , 51, 957-972	36.3	217
42	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 1512-1518	9.9	9
41	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 899-911	18.1	61
40	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 3013-3022	15.1	30
39	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 353-360	5.1	6
38	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , <b>2019</b> , 139, 1483-1492	16.7	288
37	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 473-480	16.2	21
36	Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204352	3.7	2
35	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , <b>2018</b> , 39, 3810-3820	9.5	18
34	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. <i>International Journal of Cardiology</i> , <b>2018</b> , 270, 245-252	3.2	34
33	Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	5
32	Potent P2Y Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1549-1559	15.1	36
31	Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182115	3.7	10
30	Soluble interleukin-13 receptor: a circulating regulator of glucose. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2017</b> , 313, E663-E671	6	4
29	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , <b>2016</b> , 99, 40-55	11	61
28	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , <b>2016</b> , 99, 22-39	11	42

27	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. <i>Circulation</i> , <b>2016</b> , 133, 248-55	16.7	23
26	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. <i>American Journal of Human Genetics</i> , <b>2016</b> , 99, 8-21	11	47
25	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	76
24	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1591-9	27.4	144
23	Women and Heart Attacks. <i>Circulation</i> , <b>2016</b> , 133, e428-9	16.7	2
22	Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromeE trial. <i>American Heart Journal</i> , <b>2015</b> , 169, 622-630.e6	4.9	27
21	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation□ <i>European Heart Journal</i> , <b>2015</b> , 36, 1470-7	9.5	42
20	Lipoprotein(a) for risk assessment in patients with established coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 520-7	15.1	119
19	Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 130-2	14.8	5
18	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1006-15	27.4	285
17	Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 1275-81	5	31
16	Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2349-2359	15.1	126
15	An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 106-11	15.1	69
14	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 36-43	5.1	14
13	Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , <b>2011</b> , 162, 613-619.e1	4.9	69
12	Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 1311-7	5.5	8
11	Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin□ Acute Coronary Syndromes Trial. <i>Circulation</i> , <b>2011</b> , 123, 1843-53	16.7	130
10	Natriuretic peptides in heart failure: should therapy be guided by BNP levels?. <i>Nature Reviews Cardiology</i> , <b>2010</b> , 7, 13-20	14.8	53

9	The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. <i>Journal of the American College of</i>	15.1	94
8	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet, The</i> , <b>2009</b> , 374, 989-997	40	531
7	Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 71-80	27.4	314
6	Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. <i>European Heart Journal</i> , <b>2008</b> , 29, 984-91	9.5	40
5	The future of biomarkers in the management of patients with acute coronary syndromes. <i>Current Opinion in Cardiology</i> , <b>2008</b> , 23, 309-14	2.1	12
4	Appropriate invasive and conservative treatment approaches for patients with ST-elevation MI. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2006</b> , 8, 3-11	2.1	1
3	Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. <i>Circulation</i> , <b>2006</b> , 114, 550-7	16.7	148
2	Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. <i>Circulation</i> , <b>2006</b> , 113, 1745-52	16.7	192
1	Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. <i>Circulation</i> , <b>2006</b> , 114, e600-6	16.7	93